IL17A and inflammation: A study conducted by Bai et al. further demonstrated that IL-17A-pretreated MSCs ameliorated IR-induced acute kidney injury, reduced renal inflammation, and increased the percentage of Tregs in the kidneys, while using celecoxib to block COX-2 reversed the benefits of IL-17A-pretreated MSCs, suggesting a pivotal role for COX-2 [24].